META Group

META Group sources exclusively through European Union research and innovation consortia, having worked with over 2,000 of them. Its pipeline originates inside publicly funded R&D programs, where the firm's Research Angels embed with scientists to identify results that can be turned into commercial applications. This consortium-led model is distinct from proprietary scouting or inbound pitch desks.

It is not a venture capital firm in the traditional sense. META Group describes itself as a research accelerator and generates revenue through long-term service mandates, many tied to European Commission frameworks like the Booster program, rather than from carried interest on a committed fund. It does not disclose an internal capital pool raised from limited partners.

The firm works across the full idea-to-market spectrum, from securing initial research grants through to the first commercial sale. Its methodology covers early-stage, seed, start-up, expansion, and spin-off phases, always anchored to a specific EU-funded R&D project or consortium.

Identifiable sectors include digital health, industrial technology, robotics, energy transition and renewables, and advanced materials. Specific accelerated results on the firm's website point to vascular imaging, biomimetic bone substitutes, photoacoustic cancer theranostics, green-hydrogen electrolyser technology, and multi-functional brain sensors.

The firm's website does not disclose an equity-investment vehicle or a track record of direct balance-sheet commitments. Its economic model appears based on service fees and performance incentives tied to commercializing research outputs, rather than traditional GP/LP fund structures or co-investment platforms.